An Observational, Prospective Cohort Study to Evaluate the Safety and Efficacy of Remsima in Patients With Crohn's Disease (CD) or Ulcerative Colitis (UC)

Trial Profile

An Observational, Prospective Cohort Study to Evaluate the Safety and Efficacy of Remsima in Patients With Crohn's Disease (CD) or Ulcerative Colitis (UC)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Jun 2017

At a glance

  • Drugs Infliximab (Primary)
  • Indications Crohn's disease; Ulcerative colitis
  • Focus Adverse reactions
  • Sponsors Celltrion
  • Most Recent Events

    • 05 Jun 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Dec 2019.
    • 03 Jun 2015 Planned End Date changed from 1 Jun 2027 to 1 Jun 2026 as reported by ClinicalTrials.gov record.
    • 01 Jan 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top